275 related articles for article (PubMed ID: 26303716)
21. Neuroendocrine tumors: treatment updates.
Khagi S; Saif MW
JOP; 2013 Jul; 14(4):367-71. PubMed ID: 23846929
[TBL] [Abstract][Full Text] [Related]
22. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
Krug S; Gress TM; Michl P; Rinke A
Digestion; 2017; 96(2):67-75. PubMed ID: 28728148
[TBL] [Abstract][Full Text] [Related]
23. New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Kidd M; Modlin I
Gastroenterol Clin North Am; 2010 Sep; 39(3):615-28. PubMed ID: 20951920
[TBL] [Abstract][Full Text] [Related]
24. Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Grande E; Capdevila J; López C; Teule A; Garcia-Carbonero R;
Curr Oncol Rep; 2017 Sep; 19(11):72. PubMed ID: 28920153
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxic chemotherapy for pancreatic neuroendocrine tumors.
Okusaka T; Ueno H; Morizane C; Kondo S; Sakamoto Y; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M
J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):628-33. PubMed ID: 25940377
[TBL] [Abstract][Full Text] [Related]
26. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.
Cives M; Strosberg J
Curr Treat Options Oncol; 2017 Mar; 18(3):14. PubMed ID: 28286921
[TBL] [Abstract][Full Text] [Related]
27. Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?
Raymond E; García-Carbonero R; Wiedenmann B; Grande E; Pavel M
Cancer Metastasis Rev; 2014 Mar; 33(1):367-72. PubMed ID: 24375390
[TBL] [Abstract][Full Text] [Related]
28. Emerging treatment options for patients with gastroenteropancreatic neuroendocrine tumors.
Phan AT
Clin Adv Hematol Oncol; 2017 Apr; 15 Suppl 4(4):10-14. PubMed ID: 28654024
[No Abstract] [Full Text] [Related]
29. Pancreatic NETs: where do we stand now?
Faivre S; Castellano D; Strosberg J; González E; Salazar R
Cancer Metastasis Rev; 2014 Mar; 33(1):361-6. PubMed ID: 24452757
[TBL] [Abstract][Full Text] [Related]
30. The potential role of targeted therapies in the management of neuroendocrine tumours.
Verset G; Borbath I; Delaunoit T; Demetter P; Demolin G; Hendlisz A; Pattyn P; Pauwels S; Peeters M; Roeyen G; Van Cutsem E; Van Hootegem P; Verslype C; Van Laethem JL
Acta Gastroenterol Belg; 2009; 72(1):59-62. PubMed ID: 19402374
[TBL] [Abstract][Full Text] [Related]
31. Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.
Costa FP; Gumz B; Pasche B
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):843-54. PubMed ID: 23582923
[TBL] [Abstract][Full Text] [Related]
32. Systemic therapy for advanced pancreatic neuroendocrine tumors: an update.
Reidy-Lagunes DL
J Natl Compr Canc Netw; 2012 Jun; 10(6):777-83. PubMed ID: 22679119
[TBL] [Abstract][Full Text] [Related]
33. Pancreatic neuroendocrine tumors: entering a new era.
Oberstein PE; Remotti H; Saif MW; Libutti SK
JOP; 2012 Mar; 13(2):169-73. PubMed ID: 22406593
[TBL] [Abstract][Full Text] [Related]
34. An update on gastroenteropancreatic neuroendocrine tumors.
Cives M; Strosberg J
Oncology (Williston Park); 2014 Sep; 28(9):749-56, 758. PubMed ID: 25224471
[TBL] [Abstract][Full Text] [Related]
35. Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract.
Vicentini C; Fassan M; D'Angelo E; Corbo V; Silvestris N; Nuovo GJ; Scarpa A
Molecules; 2014 Feb; 19(2):2458-68. PubMed ID: 24566314
[TBL] [Abstract][Full Text] [Related]
36. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
Chan JA; Kulke MH
Surg Oncol Clin N Am; 2016 Apr; 25(2):423-37. PubMed ID: 27013373
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
[TBL] [Abstract][Full Text] [Related]
38. Streptozocin-based chemotherapy is not history in neuroendocrine tumours.
Weatherstone K; Meyer T
Target Oncol; 2012 Sep; 7(3):161-8. PubMed ID: 22899468
[TBL] [Abstract][Full Text] [Related]
39. Refining the management of patients with gastroenteropancreatic neuroendocrine tumors.
Iyer R
Clin Adv Hematol Oncol; 2017 Apr; 15 Suppl 4(4):3-10. PubMed ID: 28654023
[No Abstract] [Full Text] [Related]
40. Therapy innovation for the treatment of pancreatic neuroendocrine tumors.
Riccardi F; Rizzo M; Festino L; Ambrosio F; Molino C; Uomo G; Cartenì G
Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S91-102. PubMed ID: 22372544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
